Nortis is a biotech company with locations in Seattle and Woodinville, WA. Founded by former UW faculty and spun-out in 2012, Nortis has developed technologies for generating small segments of human tissues and organs in microfluidic chips for the in vitro study of human health and disease.
The technology represents an important alternative to lab animals in pharmaceutical drug development, where more predictive preclinical test models are urgently needed to increase clinical trial success. This advance will overcome a large barrier to developing therapeutic drugs and vaccines for diseases like cancer, diabetes, Alzheimer’s disease, infectious diseases, cardiovascular disease, and stroke.
Nortis' vision is to facilitate groundbreaking scientific discoveries and accelerate their impact on improving human health, safety, and quality of life.
Nortis provides an efficient, affordable alternative to animal testing that can accelerate research and advance scientific exploration. By supporting fluid flow, 3D tissue culture, and robust analysis in one scalable, user-friendly platform, Nortis offers a flexible approach to drive human health research and drug development.
Nortis can provide model development services by scientifically engineering a variety of 3D tissue microenvironments. The functional unit of the organ can be exposed engineered tissues to shear stress via fluidic perfusion of media.
We can perform real-time visualization under variable conditions through various microscopy techniques. We are able to collect effluent and cell lysate for further analysis.
Cytoxicity assays including biomarkers and live/dead particle counting on vascular injury, nephrotoxicity, sinusoidal toxicity
Nortis, Inc. has not received any reviews.
Nortis, Inc. has not received any endorsements.